Podcasts about circulating

  • 390PODCASTS
  • 527EPISODES
  • 33mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • May 9, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about circulating

Latest podcast episodes about circulating

Research To Practice | Oncology Videos
Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later May 9, 2025 37:30


Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

The Energy of Money Podcast
Circulating the Energy of Money with Tom LeNoble

The Energy of Money Podcast

Play Episode Listen Later May 1, 2025 26:14


"The biggest mistake is a mindset of scarcity—the fear that there's never enough. The solution is to begin circulating money. Even small acts matter." – Tom LeNoble

History 21: The Podcast!
History 21 The Podcast - 5.08 Chelsea and the Circulating Pines

History 21: The Podcast!

Play Episode Listen Later Apr 18, 2025 35:04


Look for the show notes at AnokaCountyHistory.org

Gamereactor TV - English
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - English

Play Episode Listen Later Apr 17, 2025 3:56


Gamereactor TV - Norge
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - Norge

Play Episode Listen Later Apr 17, 2025 3:56


Gamereactor TV - Italiano
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - Italiano

Play Episode Listen Later Apr 17, 2025 3:56


Gamereactor TV - Español
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - Español

Play Episode Listen Later Apr 17, 2025 3:56


Gamereactor TV - Inglês
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - Inglês

Play Episode Listen Later Apr 17, 2025 3:56


Gamereactor TV - Sverige
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - Sverige

Play Episode Listen Later Apr 17, 2025 3:56


Gamereactor TV - Germany
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - Germany

Play Episode Listen Later Apr 17, 2025 3:56


Gamereactor TV - France
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - France

Play Episode Listen Later Apr 17, 2025 3:56


Gamereactor TV - Suomi
GRTV News - There's a The Witcher 4 beta scam currently circulating

Gamereactor TV - Suomi

Play Episode Listen Later Apr 17, 2025 3:56


The Buttonista
Circulating at Spa Mirbeau

The Buttonista

Play Episode Listen Later Mar 11, 2025 64:47


Thank God It's Tuesday! We are having a zen day at Spa Mirbeau, hanging out from the Aqua Terrace after a glow facial and plenty of time bouncing from sauna to steam room to shower. We catch up on Intern Aaron's college-y weekend, the latest in documentary TV and play a good old game of Roast or Toast.The Buttonista Show is presented by Michelob Ultra

JACC Speciality Journals
Sex Differences in the Prognostic Value of Circulating Biomarkers in Patients Presenting With Acute Chest Pain - JACC: Advances

JACC Speciality Journals

Play Episode Listen Later Feb 26, 2025 2:47


Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in the Prognostic Value of Circulating Biomarkers in Patients Presenting With Acute Chest Pain

The Joyce Kaufman Show
Joyce's Thought of the Day 2/25/25 - Fake quotes from Muslim leaders condemning Hamas are circulating the internet

The Joyce Kaufman Show

Play Episode Listen Later Feb 25, 2025 3:23


Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Joyce Kaufman Show
Joyce's Thought of the Day 2/25/25 - Fake quotes from Muslim leaders condemning Hamas are circulating the internet

The Joyce Kaufman Show

Play Episode Listen Later Feb 25, 2025 2:53


Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

AmericanReef - Saltwater and Coral Reef Aquarium Advanced Aquarists Edition
Did replacing most smaller circulating pumps with two larger ones affect the Paletta 500 reef tank?

AmericanReef - Saltwater and Coral Reef Aquarium Advanced Aquarists Edition

Play Episode Listen Later Feb 10, 2025 43:56


On this episode of AmericanReef, we take a look at the Paletta 500 gallon reef tank 3 months after he replaced most all of the smaller circulating pumps with two larger ones.

NSPR Headlines
North State ICE sightings circulating on social media likely false claims

NSPR Headlines

Play Episode Listen Later Feb 3, 2025 6:03


There have been reported sightings of ICE agents across the North State on social media. But local organizations and law enforcement agencies report most are likely false alarms. Also, Chico State President Steve Perez sent a message to the campus community last week in response to worries about the school's fiscal situation amid a freeze on federal funding, and the second manual snow survey of the season measured 22 inches of snow depth, only 46 percent of average for the location near Echo Summit.

Dave and Dujanovic
The 'Quademic' circulating the US

Dave and Dujanovic

Play Episode Listen Later Feb 3, 2025 10:14


Do you know someone who is sick right now? There is a "Quademic" going around..  as referred to by health officials. 4 major viruses circulating in the US... Lois Collins with the Deseret News breaks down what you need to know about the viruses impacting Americans.

JCO Precision Oncology Conversations
ctDNA as a Prognostic Biomarker in EGC

JCO Precision Oncology Conversations

Play Episode Listen Later Jan 29, 2025 5:51


In this JCO PO Article Insights episode, Harold Nathan Tan summarizes findings from the JCO PO article, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host for today's episode. Let's dive into a fascinating study published in JCO Precision Oncology entitled, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” This study led by Dr. Eric Michael Lander and colleagues examines a critical question: Can circulating tumor DNA help predict recurrence in patients with esophagogastric cancer who have achieved a favorable pathologic response after treatment? Esophagogastric cancer ranks as the seventh leading cause of cancer-related deaths worldwide. Despite aggressive treatment including neoadjuvant therapy followed by surgery, recurrence remains a grim reality for many patients. Interestingly, even those who achieve a pathologic complete response face a recurrence risk of up to 25%. This highlights a need for better tools to identify high-risk patients post-treatment. Circulating tumor DNA, or ctDNA for short, is emerging as a powerful biomarker in oncology. This minimally invasive blood-based test detects fragments of tumor DNA in the bloodstream, potentially signaling molecular residual disease before any radiographic evidence of recurrence appears. In this study, researchers focused on patients with locoregional esophagogastric cancer who had undergone neoadjuvant therapy followed by surgery, achieving either a complete or near complete pathologic response. Blood samples were collected postoperatively within a 16-week molecular residual disease window and during routine surveillance. The aim is to determine whether ctDNA positivity correlates with recurrence-free survival. The study analyzed 309 plasma samples from 42 patients across 11 institutions. Detectable ctDNA within the 16-week postoperative window was associated with a significantly higher recurrence risk. Among those with detectable ctDNA, 67% experienced recurrence compared to only 15% for those with undetectable ctDNA. This corresponds to a hazard ratio of 6.2, an alarming figure that underscores the potential for ctDNA as a prognostic tool. But the story doesn't end there. Postoperative surveillance ctDNA testing more than 16 weeks after surgery also proved to be a powerful prognostic indicator. Every patient with detectable ctDNA during surveillance eventually experienced recurrence, while only 7.4% of those with undetectable ctDNA relapse. These findings suggest that ctDNA testing could provide a critical lead time, enabling earlier interventions and personalized treatment strategies. Now let's talk about the clinical implications. Currently, patients who achieve a pathologic complete response often aren't considered for adjuvant therapies as the absence of visible disease is taken as a sign of remission. However, this study challenges that assumption. By integrating ctDNA testing into routine post-treatment surveillance, clinicians could identify high-risk patients who might benefit from additional therapy even when traditional imaging shows no signs of recurrence. This brings us to the bigger picture. Esophagogastric cancer treatment is evolving rapidly, with trials like CheckMate 577 and ESOPEC offering new insights into perioperative strategies. However, this study highlights a critical gap, the need for personalized, biomarker-driven approaches in the adjuvant setting. ctDNA could fill that gap, offering a non-invasive, dynamic way to monitor patients and guide clinical decisions. Of course, no study is without its limitations. The authors acknowledge the relatively small sample size and the retrospective nature of their analysis. They also note the variability in ctDNA testing and imaging schedules across institutions. However, the robust association between ctDNA positivity and recurrence-free survival makes a compelling case for further research in larger prospective cohorts. Looking ahead, what's the next step? The authors call for prospective validation of ctDNA as a prognostic tool, emphasizing its potential to refine risk stratification and optimize treatment strategies. Imagine a future where a simple blood test could dictate not only the need for additional therapies, but also the timing and type of intervention. As we wrap up, let's reflect on the broader impact of the study. By integrating ctDNA into routine cancer care, we could move closer to a world where treatments are not just effective, but also precisely tailored to each patient's unique biology and disease dynamics. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

The Fortnite Podcast
CLIX GETS AMBUSHED BY HIS TRIO AND LEFT SOLO! .. LAN RUMORS ARE CIRCULATING??? and Much More!

The Fortnite Podcast

Play Episode Listen Later Jan 21, 2025 58:10


Join our NEW Community Discord! https://www.discord.gg/podcast Today's topics we cover Epic's unforeseen job at handling cheaters. Topics: 1. Clix has his trio snake him in the final week! 2. Will the next LAN be in Raleigh or France? 3. Will Fortnite Competitive officially support the a new game mode? 4. Tune into the Comp awards! https://x.com/CompAwardsFN Follow Us On Twitter: MonsterDface - @MonsterDface Somebodysgun - @Somebodysgun LifeWithPanda - @LifewPanda  Email all of your complaints to us on twitter. Don't forget to leave us a comment!

The Book Drop
184. Top Circulating Titles at OPL in 2024

The Book Drop

Play Episode Listen Later Jan 17, 2025 42:37


This week on The Book Drop, we take a deeper look at the top circulating titles of 2024 for OPL, and discuss what they reveal about our community's awesome reading habits. This is The Book Drop.All the books and resources we talk about in this episode can be found at omahalibrary.org/podcast and here. Happening at the Library: Oregon Trail Live Action | Saturday, Jan. 18 | 1 to 3 p.m. | Saddlebrook Branch and Thursday, Jan. 23 | 6 to 7p.m. | Millard Branch Container Gardening Workshop | Tuesday, Jan. 21 | 10:30 to 11:30 a.m. | Swanson Branch Writer's Workshop | Tuesday, Jan. 21 | 5:30 to 7:30 p.m. | Benson Branch Explore all upcoming events at omahalibrary.org/events.

Health Newsfeed – Johns Hopkins Medicine Podcasts
How does circulating DNA contribute to accelerated aging? Elizabeth Tracey reports

Health Newsfeed – Johns Hopkins Medicine Podcasts

Play Episode Listen Later Jan 12, 2025 1:04


DNA fragments found in your blood, so called circulating cell free DNA, come from your cells as they die. Both genetic material and DNA from your energy plants, known as mitochondria, can be found, and both are implicated in increased … How does circulating DNA contribute to accelerated aging? Elizabeth Tracey reports Read More »

Health Newsfeed – Johns Hopkins Medicine Podcasts
Are circulating DNA and inflammation related? Elizabeth Tracey reports

Health Newsfeed – Johns Hopkins Medicine Podcasts

Play Episode Listen Later Jan 12, 2025 1:04


Circulating cell free DNA fragments are found in your bloodstream when cells die and release what's inside. Some of that DNA is your genetic material and some comes from mitochondria, the power plants of your cells. Johns Hopkins geriatrics expert … Are circulating DNA and inflammation related? Elizabeth Tracey reports Read More »

Health Newsfeed – Johns Hopkins Medicine Podcasts
Higher levels of your own DNA circulating in your blood may be a problem, Elizabeth Tracey reports

Health Newsfeed – Johns Hopkins Medicine Podcasts

Play Episode Listen Later Jan 12, 2025 1:03


DNA fragments found circulating in an older person's blood are associated with frailty and Alzheimer's disease, studies by Peter Abadir, a geriatrics expert at Johns Hopkins, and colleagues have shown. These long term studies of several hundred older adults also … Higher levels of your own DNA circulating in your blood may be a problem, Elizabeth Tracey reports Read More »

EAU Podcasts
Kidney cancer - Take home messages for 2024

EAU Podcasts

Play Episode Listen Later Dec 29, 2024 13:51


The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk and Dr. Riccardo Bertolo share highlights of the important kidney cancer developments for 2024. They summarise the results on several important trials such as FASTRACK, ZIRCON, KEYNOTE-564 and IMmotion010. They also discuss the developments on surgical aspects too.To learn more on the highlights discussed in this podcast, you can read the below Articles of the Month, listen to the podcasts or watch the videos.Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialASCO GU24 special: Assoc. Prof. Barata discusses the results of KEYNOTE-564 and CheckMate-914ASCO GU24 special: Prof. Michael Hofman talks about a novel CA IX-targeting peptideASCO2024 special: Circulating kidney injury molecule-1 biomarker analysis in IMmotion010Present and future of robotic surgery for RCCThe treatment of locally advanced and metastatic renal cancerFor more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, Google Podcasts.

RETINA Journal Podcasts
RB1 CIRCULATING TUMOR DNA IN THE BLOOD OF PATIENTS WITH RETINOBLASTOMA INCREASES IN UNTREATED PATIENTS

RETINA Journal Podcasts

Play Episode Listen Later Dec 17, 2024 6:05


Smallzy's Surgery
ALERT: Black Friday Scam Circulating Online!

Smallzy's Surgery

Play Episode Listen Later Nov 28, 2024 4:39 Transcription Available


See omnystudio.com/listener for privacy information.

Research To Practice | Oncology Videos
ER-Positive Metastatic Breast Cancer | 5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Nov 26, 2024 10:56


Featuring an interview with Dr Seth Wander, including the following topics: ASCO Guidelines Rapid Recommendations Update for Testing for ESR1 Mutations (0:00) Real-world elacestrant use patterns and genomic biomarkers (4:43) Circulating tumor DNA (ctDNA) analyses with imlunestrant in the EMBER Phase I study (8:50) CME information and select publications

The James Cancer-Free World Podcast
Episode 177: Advances in Liquid Biopsies & Circulating Tumor DNA, with Dr. Sameek Roychowdhury

The James Cancer-Free World Podcast

Play Episode Listen Later Nov 18, 2024 41:07


Liquid biopsies and circulating tumor DNA are changing and improving the way cancer is detected and treated. In this episode, Sameek Roychowdhury, PhD, MD, explains the basics of circulating tumor DNA, how it's being used at the James, his lab's clinical trials, and the promising future. “When a normal cell and a cancer die they sheds fragments of their DNA,” he said. “Cancer can be detected in the blood by looking for these fragments and this is becoming an important research tool and treatment tool for the care of cancer patients.” For example, about 50 percent of cancer patients who have a tumor surgically removed will have a recurrence. And it's very difficult to determine which patients will have the recurrence. Minimally invasive liquid biopsies after surgery “helps us stratify and determine patients with a lesser recurrence risk who won't need chemotherapy or immunotherapy treatment versus those patients who need even more treatment than we've normally given them in the past.” Monitoring circulating tumor DNA “also becomes part of the surveillance program and we'll do a precise test every three months that measures fragments in the blood,” Roychowdhury said, adding that finding a recurrence of cancer from these fragments, months before it would appear on more traditional scans “allows us to make a diagnosis about the molecular drivers of the cancer and we can begin treatment earlier and better understand which treatment options will work best.”

The EMJ Podcast: Insights For Healthcare Professionals
Onc Now: Episode 3: Redefining Breast Cancer

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Nov 4, 2024 46:13


This week, Jonathan Sackier is joined by Carlos Caldas, a world-leading expert in breast cancer research and clinician scientist at the University of Cambridge. Together, they explore how genomic-based classifications of breast cancer are transforming treatment strategies and improving patient outcomes.  Timestamps:  (00:00) – Introduction  (02:00) – Carlos's favourite cuisine   (03:32) – Carlos's journey into oncology   (08:30) – The redefinition of breast cancer   (14:30) – How this taxonomy influences clinical care   (20:15) - Patient-derived xenografts for breast cancer   (28:00) - Circulating plasma cell-free tumour DNA as a marker of tumour burden   (33:00) – Patient derived tumour cells for drug screening   (35:00) – Vitamin B5 and environmental factors in oncology   (38:44) – Current developments in breast cancer aetiology, diagnosis or treatment    (44:00) – The three wishes for the future of healthcare   (45:00) – Outro  

Living Beyond 120
Q&A: Pregnancy Health, Breast Cancer, Youthful Lungs, and Dental Hygiene - Episode 259

Living Beyond 120

Play Episode Listen Later Oct 31, 2024 52:34 Transcription Available


In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Steve Reiter discuss various aspects of health optimization, focusing on longevity, pregnancy health, and breast cancer awareness. They explore innovative therapies like ozone treatment and detoxification methods, as well as provide actionable recommendations for couples planning for pregnancy. The conversation also addresses common myths surrounding breast cancer, emphasizing the importance of genetics and regular screenings. In this episode, the conversation delves into various aspects of cancer detection, treatment, and overall health maintenance. The discussion highlights the importance of understanding cancer testing methods, the reality of remission, and innovative therapies that support the immune system. Additionally, the episode emphasizes the significance of lung health through exercise and the critical role of dental hygiene in overall health. The conversation concludes with exciting developments in rejuvenation procedures that promise significant health benefits.   For the audience ·      Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways   ·      The mitochondria play a crucial role in energy production and immune response. ·      Ozone therapy can rejuvenate mitochondrial function and aid in detoxification. ·      Frequent sexual activity can improve reproductive health for men. ·      Inositol can help women with PCOS improve their chances of pregnancy. ·      Adequate iodine levels can significantly impact a baby's IQ. ·      Regular exercise is beneficial for both pregnancy and overall health. ·      Avoiding heat exposure is important for male fertility. ·      Genetic testing can provide insights into breast cancer risk. ·      Mammograms are not the only screening method for breast cancer. ·      Circulating tumor cell tests can detect cancer earlier than traditional methods.  ·      Circulating tumor cells are crucial for cancer detection. ·      Remission does not mean the absence of cancer. ·      Innovative therapies can enhance immune response against cancer. ·      Exercise is vital for maintaining lung health. ·      Dental hygiene impacts systemic health significantly. ·      Root canals may lead to latent infections affecting health. ·      Regular exercise improves outcomes for cancer patients. ·      Breathing techniques can enhance lung function during exercise. ·      New rejuvenation procedures show promising results for recovery. ·      Understanding oral bacteria is essential for overall health.   Chapters   00:00 Introduction to Age Hacking and Longevity 10:01 Health Recommendations for Pregnancy: Answering a Listener's Q 21:44 Breast Cancer Awareness and Myths 26:09 Understanding Cancer Detection and Testing 28:50 The Reality of Cancer Remission 30:43 Innovative Cancer Therapies and Immune System Support 35:02 Enhancing Lung Health Through Exercise 43:00 The Importance of Dental Hygiene 48:43 Exciting Developments in Rejuvenation Procedures   Articles, News and Supplements mentioned Breast Cancer BREAST CANCER MYTHS https://www.wkrn.com/news/tennessee-news/breast-cancer-awareness-month-common-myths-about-the-disease/   BREAST CANCER GUIDE EVERYONE SHOULD HAVE https://www.telegraph.co.uk/health-fitness/conditions/cancer/breast-cancer/   NEW TECH FOR CANCER SCREENING https://www.cbsnews.com/chicago/news/doctor-talks-new-technology-importance-of-breast-cancer-screenings/   NEW WAY TO KILL CANCER CELLS https://medicalxpress.com/news/2024-10-cancer-cells-longer-people-breast.html   Healthy Lungs BENEFITS OF EXERCISE FOR PATIENTS WITH LUNG CANCER https://medicalxpress.com/news/2024-10-people-lung-cancer-grueling-evidence.html   HABITS PULMONOLOGISTS ARE BEGGING PEOPLE TO ADOPT AND DITCH https://parade.com/health/the-one-habit-to-adopt-asap-if-you-have-severe-asthma-according-to-pulmonologists   Dental Hygiene DENTAL HEALTH SENSING WITH SONIC TOOTHBRUSH https://medicalxpress.com/news/2024-10-exploring-dental-health-sonic-toothbrush.html   DENTAL HYGIENIST TALKS ABOUT HOW TO SPOT PERIODONTAL DISEASE https://www.buzzfeed.com/meganeliscomb/smell-your-used-floss-tiktok   UGLY YET MOST HIGHLY EFFECTIVE TOOTHBRUSH REVIEWERS HAVE EVER USED https://www.huffpost.com/entry/flossing-toothbrush_l_66fefb0de4b089d324aa50b1/amp   Supplements MOLECULAR HYDROGEN – ENERGY https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-30-ct   MOLECULAR HYDROGEN – CHILL https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-product-h2-chill   TOOTH AND GUM ESSENTIALS TOOTH PASTE https://gladdenlongevityshop.com/products/tooth-gum-essentials-toothpaste-4oz-1?_pos=1&_psq=dental&_ss=e&_v=1.0   TOOTH AND GUM TONICS https://gladdenlongevityshop.com/products/tooth-gum-tonic-18-fl-oz-1?_pos=2&_psq=dental&_ss=e&_v=1.0    UPGRADED IODINE https://gladdenlongevityshop.com/products/upgraded-memory-4fl-oz?pr_prod_strat=e5_desc&pr_rec_id=ec1b1eb28&pr_rec_pid=8125057761519&pr_ref_pid=8125058580719&pr_seq=uniform    ZINC https://gladdenlongevityshop.com/products/zinc-glycinate-120-gels-1?_pos=1&_psq=zinc&_ss=e&_v=1.0    Send your Qs for future episodes! Email: podcast@gladdenlongevity.com   Reach out to us at: Website: https://gladdenlongevity.com/  Facebook: https://www.facebook.com/Gladdenlongevity/ Instagram: https://www.instagram.com/gladdenlongevity/?hl=en  LinkedIn: https://www.linkedin.com/company/gladdenlongevity YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw 

The EMJ Podcast: Insights For Healthcare Professionals
Onc Now: Episode 3: Redefining Breast Cancer

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Oct 23, 2024 46:14


This week, Jonathan Sackier is joined by Prof. Carlos Caldas, a world-leading expert in breast cancer research and clinician scientist at the University of Cambridge. Together, they explore how genomic-based classifications of breast cancer are transforming treatment strategies and improving patient outcomes.  Timestamps: (00:00) – Introduction  (02:00) – Carlos's favourite cuisine   (03:32) – Carlos's journey into oncology   (08:30) – The redefinition of breast cancer   (14:30) – How this taxonomy influences clinical care   (20:15) - Patient-derived xenografts for breast cancer   (28:00) - Circulating plasma cell-free tumour DNA as a marker of tumour burden   (33:00) – Patient derived tumour cells for drug screening   (35:00) – Vitamin B5 and environmental factors in oncology   (38:44) – Current developments in breast cancer aetiology, diagnosis or treatment    (44:00) – The three wishes for the future of healthcare   (45:00) – Outro

Fitness mit M.A.R.K. — Dein Nackt Gut Aussehen Podcast übers Abnehmen, Muskelaufbau und Motivation
Solltest Du Vitamin D einnehmen? Das sagt die Wissenschaft (#494)

Fitness mit M.A.R.K. — Dein Nackt Gut Aussehen Podcast übers Abnehmen, Muskelaufbau und Motivation

Play Episode Listen Later Oct 21, 2024 40:03


Was man teilweise über Vitamin D hört, klingt fast zu schön, um wahr zu sein. Andererseits deuten hunderte verschiedener Forschungsarbeiten darauf hin, dass Vitamin D zur Vorbeugung einer Reihe von Krankheiten beitragen kann – darunter Osteoporose, Depression, Autoimmun- und Herz-Kreislauf-Erkrankungen. Ärzte empfehlen es. Gesundheits- und Fitnesspodcaster sprechen darüber. Vielleicht geht Dir sogar Deine Lieblingstante damit auf die Nerven. Bei all dem Hype ist die Frage berechtigt: "Solltest Du Vitamin D einnehmen?" Hier sind die Antworten – und die neuesten Fakten über ein faszinierendes Vitamin, das ein wahrer Verwandlungskünstler ist. ____________ *WERBUNG: KoRoDrogerie.de: 5% Ermäßigung auf alles mit dem Code „FMM“ beim Checkout. ____________ Ressourcen zur Folge: Literatur: Ratgeber Nahrungsergänzung – Mark Maslow (kostenlos auf MarathonFitness) Blut: Die Geheimnisse unseres flüssigen Organs* – Ulrich Strunz (Heyne) Vitamin D* – Uwe Gröber, Michael F. Holick (Wissenschaftl. Verlagsgesellschaft) Blutuntersuchung (Selbsttest): Vitamin D Test* von Medivere Präparate: D-Form 2.000 K2+* von FormMed D-Form 2.000 K2+ vegan* von FormMed ____________

covid-19 women health man food depression medicine cancer institute nutrition journal patients disease treatments hype effects comparison deutschland prevention diabetes bone bei implications committee ideen antworten older essen gesundheit vielleicht hughes khan clinical outcomes li function evaluation obesity edited ky vitamins checkout reihe fakten sonne wang vitamin d progression advances american society american colleges norton immune system metabolism ressourcen krankheiten sagt zhang internal medicine anne marie nerven yin magnesium mena sunlight efficacy international journal k2 nutrients cardiology american journal critical role chronic disease johansson calcium functioning prevalence aufruf circulation new england journal vitamine erm resta kimball predictors solltest du clinical research annals andererseits american federation deng valerio gesundheits clinical nutrition british journal meta analysis preventive medicine european journal wl beckman cashman die wissenschaft jutta palumbo older men zito reinhold circulating vitamin k vorbeugung observational wacker atherosclerosis life stages osteoporose younger men mandal herz kreislauf erkrankungen nutritional supplements mineralien michael f mineralstoffe anglin sun exposure vitamin d deficiency kevin d quaranta respiratory health einnehmen clinical implications clinical studies versorgungslage forschungsarbeiten clinical endocrinology endocrine society cureus us population maria g glycemic control vieth am j clin nutr postmenopausal women vitamin d supplementation american osteopathic association markus k autoimmun developed countries earthman mark maslow xinyi mariana costa melhus vitamin d2 verwandlungsk pittas dierkes medical hypotheses mental science experimental immunology nutrition examination survey nhanes samantha m vitamin d status masterjohn bmc medicine mineral research dietary reference intakes calcitriol vanita r aroda michael f holick joann e manson catharine ross
Oncology Times - OT Broadcasts from the iPad Archives
Circulating Tumor DNA Directs Precision Management for Ovarian Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 15, 2024 10:01


Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology Innovation at UCLA, where he is also Chief of Cytopathology and Director of International Telepathology. At the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, Rao gave Oncology Times reporter Peter Goodwin details of the molecular methods he had just outlined to the conference.

The Kyle & Jackie O Show

The Kyle & Jackie O Show

Play Episode Listen Later Oct 10, 2024 6:23 Transcription Available


A wild Beyonce conspiracy theory is taking hold, so we're going to explain it. P Diddy's scandals have had people asking who else might be involved, and a lot of attention has landed on Jay Z and Beyonce. Have a listen for all the juicy details...See omnystudio.com/listener for privacy information.

Eat to Live
Anti-Aging and Longevity

Eat to Live

Play Episode Listen Later Oct 9, 2024 43:27


ReferencesChitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway.Clin Cancer Res 2008,14:6364-6370.Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene.Arch Physiol Biochem 2009, 115:58-71.Davies M, Gupta S, Goldspink G, Winslet M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.Int J Colorectal Dis 2006, 21:201-208.Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer.J Natl Cancer Inst 2002, 94:972-980.Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence.Novartis Found Symp 2004, 262:247-260; discussion 260-268.Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging.Science 1997, 278:419-424.Doi T, Shimada H, Makizako H, et al. Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed.Neurobiol Aging 2015, 36:942-947.Calvo D, Gunstad J, Miller LA, et al. Higher serum insulin-like growth factor-1 is associated with better cognitive performance in persons with mild cognitive impairment.Psychogeriatrics 2013, 13:170-174.Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors.Endocr Rev 1994,15:80-101.Clemmons DR, Seek MM, Underwood LE. Supplemental essential amino acids augment the somatomedin-C/insulin-like growth factor I response to refeeding after fasting.Metabolism 1985, 34:391-395.Runchey SS, Pollak MN, Valsta LM, et al. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study.Eur J Clin Nutr 2012, 66:1146-1152.Brand-Miller JC, Liu V, Petocz P, Baxter RC. The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects.Am J Clin Nutr 2005, 82:350-354.Biddinger SB, Ludwig DS. The insulin-like growth factor axis: a potential link between glycemic index and cancer.Am J Clin Nutr 2005, 82:277-278.Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality.J Clin Endocrinol Metab 2011, 96:2912-2920.Ranke MB, Osterziel KJ, Schweizer R, et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays.Clin Chem Lab Med 2003, 41:1329-1334.Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations.J Clin Endocrinol Metab 2014, 99:1712-1721.Brabant G, von zur Muhlen A, Wuster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study.Horm Res 2003, 60:53-60.Crowe FL, Key TJ, Allen NE, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition.Cancer Epidemiol Biomarkers Prev 2009,18:1333-1340.Fontana L, Klein S, Holloszy JO. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk.Am J Clin Nutr 2006, 84:1456-1462.Fontana L, Weiss EP, Villareal DT, et al. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans.Aging Cell 2008, 7:681-687.Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations.J Clin Endocrinol Metab 2009, 94:1732-1739.Carlzon D, Svensson J, Petzold M, et al. Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men.J Clin Endocrinol Metab 2014, 99:E2308-2316.Svensson J, Carlzon D, Petzold M, et al. Both low and high serum IGF-I levels associate with cancer mortality in older men.J Clin Endocrinol Metab 2012, 97:4623-4630. .van Bunderen CC, van Nieuwpoort IC, van Schoor NM, et al. The Association of Serum Insulin-Like Growth Factor-I with Mortality, Cardiovascular Disease, and Cancer in the Elderly: A Population-Based Study.J Clin Endocrinol Metab 2010.Arai Y, Takayama M, Gondo Y, et al. Adipose endocrine function, insulin-like growth factor-1 axis, and exceptional survival beyond 100 years of age.J Gerontol A Biol Sci Med Sci 2008, 63:1209-1218.Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke.J Clin Endocrinol Metab 2005, 90:5937-5941.Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.Lancet 1998, 351:1393-1396.Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.Science 1998, 279:563-566.

Fully Functional Parents
Circulating Hot Air: The Year of Us!

Fully Functional Parents

Play Episode Listen Later Oct 7, 2024 16:34


Remember when I was diagnosed with cancer? remember that thing growing on our kid's neck? Remember when our kid had a seizure? What a year!! Oh and David's too helpful! Stop helping, David!!

The Syneos Health Podcast
Circulating Tumor DNA: Transforming Oncology Clinical Trials

The Syneos Health Podcast

Play Episode Listen Later Oct 2, 2024 20:01


Use of circulating tumor DNA (ctDNA) – small fragments of DNA that are released into the bloodstream by cancer cells – as a diagnostic tool represents a significant shift toward more precise, personalized cancer care, enhancing both trial efficiency and patient experience. Unlike traditional tissue biopsies, which sample a single tumor site, ctDNA offers a real-time, comprehensive view of the genetic mutations present in the tumor throughout the body. By offering faster, more detailed insights than traditional imaging, ctDNA can identify tumor mutations earlier and help clinicians adjust treatments sooner.In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Dr. Patrick Kelly and Dr. Wael Harb to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Find all of our oncology-related insights on our Insights Hub here.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Bizarre Encounters
Bizarre Inquiries #14 "What conspiracy theories are circulating the 2024 election?"

Bizarre Encounters

Play Episode Listen Later Aug 22, 2024 29:05


WATCH ON YOUTUBE: https://youtu.be/ZNzsha1XJwE.Join Shayn & Orin as we discuss what conspiracy theories are circulating the 2024 election. Thanks for checking out the 14th episode of "Bizarre Inquiries". Don't forget to submit your own bizarre inquiry, clip, or article for us to discuss on the show!Do us a favor and like, follow, share, & leave a review! We appreciate it!.Article: https://www.thedailybeast.com/the-most-outrageous-conspiracy-theories-of-the-2024-election-yet.Do you want join the discussion on this weeks bizarre inquiry?Join the discord and post your thoughts in the "Bizarre Inquiries" channelhttps://discord.com/invite/pPNa84ZEjp.*4 NEW MERCH DESIGNS AVAILABLE NOW!*Use code "CRYPTID10" for 10% off the OMM Merch Store!https://open-minds-media.creator-spring.com/.Social Media/Email/Donate/Merch/Patreonhttp://linktr.ee/open_minds_media..REPORT AN ENCOUNTERommencounterreports@outlook.com..Affiliate Link:Chattergeist by Dimension Deviceshttps://dimensiondevices.co.uk/shop.php?affiliate=OpenMindsMediahttps://www.instagram.com/dimension.devices/..Please Check Out:.Bizarre EncountersSocial Media/Email/Donate/Merch/Patreonhttp://linktr.ee/bizarreencounters..Inquiries of our Reality (Shayn)Social Media/Email/Donate/Merch/Patreonhttp://linktr.ee/inquiriesofourrealitypodcast..The Framework: UFO Research Center (Orin)https://www.instagram.com/theframeworkufo/..Open Minds Media (OMM)https://linktr.ee/open_minds_media..Phantoms & Monsters Fortean Research Teamhttps://www.phantomsandmonsters.com/p/phantoms-monsters-fortean-research.html..SPONSORS:.IKNOWSQUATCHSpreading the gospel of Squatch with knowledge & fresh merchhttps://www.etsy.com/shop/iknowsquatch?ref=shop_sugghttps://www.instagram.com/iknowsquatch/..CryptoteeologySpecializing in wearable cryptids and monsters and the stories behind them. Discover a relatable monster for any casual occasion.https://www.cryptoteeology.com/https://www.instagram.com/cryptoteeology/https://www.facebook.com/Cryptoteeology..The Snarly Yow Beard & Body ProductsSnarly Products are made exclusively for the Snarly Yow by crafters and local small businesses by hand.https://www.snarlyyow.com/https://www.instagram.com/thesnarlyyowhttps://www.facebook.com/TheSnarlyYow/..Phantoms & Monsters Fortean Research Teamhttps://www.phantomsandmonsters.com/p/phantoms-monsters-fortean-research.html..Intro & Outro By:Socio-Beathttps://distrokid.com/hyperfollow/sociobeat/conundrumhttps://socio-beat.bandcamp.com/..Support this podcast at — https://redcircle.com/bizarre-encounters/donations

Empower Project Radio
Mastering the Art of High Level Earning, Investing and Circulating Wealth // with KRISTEN WONCH

Empower Project Radio

Play Episode Listen Later Jul 22, 2024 53:18


Welcome back friends, to another episode of Empower Project Radio. I am so jazzed about this conversation today. We are talking all about MONEY. We're talking about MINDSET. We're talking about high earning and the high earning money blocks that come along with it. Join me, KC Volard, while I pick the brain of global money coach, Kristen Wonch. Check out Kristen's free program offering here. Want to see Kristen live in-person? She's a panelist alongside other multiple 6-figure earners at As She Rises LIVE in Montreal September 21-22, 2024. Do you have your ticket yet? Get yours HERE!The As She Rises Live Event is an Embodiment & Business Conference for Spiritual Entrepreneurs, Mystics, Healers and Visionaries from around the world.An epic, ground shattering and transformational event. Take a screenshot and tag me on Instagram (@iamkcvolard)!Let me know what you're loving!Let's continue the conversation over inside our FREE telegram community - The 7-Figure Coven!

Sleep Meditation for Women
Body Relaxing Affirmations for Sleep

Sleep Meditation for Women

Play Episode Listen Later Jun 28, 2024 31:18


Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

ASCO Daily News
GU Oncology Highlights from ASCO24

ASCO Daily News

Play Episode Listen Later Jun 27, 2024 34:54


Dr. Neeraj Agarwal and Dr. Rana McKay discuss promising studies in GU cancers featured at the 2024 ASCO Annual Meeting that highlighted improved outcomes in urothelial carcinoma, improved survival in renal cell carcinoma, and the role of ctDNA as a potential biomarker for predicting outcomes.   TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah's Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News.  I am delighted to welcome Dr. Rana McKay, a GU medical oncologist and associate professor at the University of California San Diego. Today, we'll be discussing some key GU abstracts featured at the 2024 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Rana, we're thrilled to have you on the podcast today to share your insights on key advances in GU oncology from ASCO24. Dr. Rana McKay: Thank you so much, Neeraj; it's a pleasure to be here. Dr. Neeraj Agarwal: So, Rana, let's start with some bladder cancer abstracts. Could you tell us about Abstract 4503, titled “Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer”? Dr. Rana McKay: Of course, I would be delighted to. First, I would like to remind our listeners that enfortumab vedotin (EV) was approved as a monotherapy for the treatment of locally advanced or metastatic urothelial cancer based on the results of EV-201 and EV-301 trials. In these pivotal studies, EV was initiated at a dose of 1.25 mg/kg, and dose modifications, such as reductions and interruptions, were used to manage adverse events. In the abstract presented at ASCO 2024, Dr. Daniel Petrylak and colleagues conducted a post-hoc exploratory analysis to evaluate the association between EV plasma exposure and outcomes. They used multiple pharmacokinetic samples collected during the first two cycles and pre-dose samples from 3 EV monotherapy studies, namely EV-101, EV-201, and EV-301, that were conducted in patients with previously treated locally advanced or metastatic urothelial carcinoma. Dose reductions to 1 mg/kg were required in 42.1% and 35.1% of patients in the EV-201 and EV-301 trials, respectively, and reductions to 0.75 mg/kg were required in 13.6% and 11.1% in the EV-201 and EV-301 trials, respectively. Higher EV exposure during the first two cycles was associated with a higher objective response rate. The ORR was 21.4% for the dose of 0.75 mg/kg, while it was 18.5% for the dose of 1.0 mg/kg. Interestingly, increasing the dosage to 1.25 mg/kg improved the ORR, which ranged from 40 to 51.1% across various studies. In the EV-301 trial, when comparing the efficacy of EV to chemotherapy, EV improved PFS and OS across all dose quartiles, and there was no evidence that recommended dose modifications impacted long-term efficacy outcomes. Dr. Neeraj Agarwal: Thank you, Rana, for this great summary. I would like to add that the meticulously conducted pharmacokinetic studies demonstrated that serum levels of EV correlated with responses. Importantly, patients who had to decrease the dose did not experience compromised outcomes as EV improved PFS and OS outcomes vs chemotherapy in across all exposure quartiles in the EV-301 trial where EV was compared with chemotherapy. These findings highlight the need to start at the recommended dose of 1.25 mg/kg and reduce it, if necessary, however, clinicians should not start at a lower dose.  Dr. Rana McKay: I totally agree with you, Neeraj. Now, moving on to a different setting in bladder cancer, what can you tell us about LBA4517, titled “Perioperative sacituzumab govitecan alone or in combination with pembrolizumab for patients with muscle-invasive urothelial bladder cancer: SURE-01/02 interim results”? Dr. Neeraj Agarwal: Of course! So, SURE was a multicohort, open-label, phase 2 study in patients with muscle-invasive bladder cancer assessing sacituzumab govitecan as a neoadjuvant therapy either alone in SURE-01 or as a combination with pembrolizumab followed by adjuvant pembro in SURE-02 in a flexible design allowing a bladder-sparing approach. In the abstract presented at ASCO 2024, Dr. Antonio Cigliola and colleagues report interim results of the SURE-01 study. Patients with cT2-4N0M0 urothelial carcinoma who were ineligible for or refused cisplatin-based neoadjuvant chemotherapy were planned to receive 4 cycles of neoadjuvant sacituzumab govitecan at a dose of 10 mg/kg followed by radical cystectomy.  An extensive assessment was performed at baseline and after the 4 cycles for response assessment. Patients with clinical complete response defined with negative MRI, cystoscopy and ctDNA assays refusing radical cystectomy were offered redo transurethral resection of the bladder tumor or repeat TURBT followed by observation in the absence of viable high-grade tumor in the bladder. The primary endpoint was pathological complete response rate, while secondary endpoints included pathological downstaging rate and safety. After the first 8 patients were enrolled, the protocol was amended due to the occurrence of grade 3 and 4 neutropenia and diarrhea in 75% and 50% of patients, respectively, and 2 deaths – one of which was deemed to be treatment-related due to sepsis. Key protocol changes included the reduction of the dose of sacituzumab govitecan to 7.5 mg/kg, the introduction of G-CSF as primary prophylaxis, and the exclusion of patients at high risk of febrile neutropenia per ASCO guidelines.  Among 21 patients who received at least one cycle of sacituzumab govitecan and included in the intention-to-treat population, 47.6% had a complete pathological response, and 52.4% had pathological downstaging. 11 patients underwent radical cystectomy, while 7 received repeat-TURBT due to complete clinical response or patient preference. Regarding the safety profile, grade 3 or more adverse events occurred in 42.5% of patients. Treatment-related adverse events leading to dose interruptions or discontinuations were more common before the protocol amendment. It is noteworthy that 3 patients died after treatment discontinuation, with one deemed treatment-related, as previously mentioned. Dr. Rana McKay: Thank you, Neeraj, for a great summary. The pathological complete responses observed show promising activity for sacituzumab govitecan as a neo-adjuvant therapy and a window for bladder-sparing approaches, which is definitely exciting news for our patients! However, although the 3 deaths encountered in a neo-adjuvant setting could be concerning, the improvement of the safety profile after protocol amendments is reassuring and supports the continuation of the study. Dr. Neeraj Agarwal: Before wrapping up the bladder cancer section, would you like to share your insights with our listeners on Abstract 4518, titled “Quantitative circulating tumor DNA (ctDNA) assessment in patients with advanced urothelial carcinoma treated with pembrolizumab or platinum-based chemotherapy from the phase 3 KEYNOTE-361 trial”?  Dr. Rana McKay: Sure. So, the KEYNOTE-361 trial was a randomized phase 3 study with 3 arms that included pembrolizumab plus chemotherapy, pembrolizumab monotherapy, or chemotherapy alone in patients with previously untreated advanced urothelial carcinoma. The results showed that neither the combination of pembrolizumab plus chemotherapy nor pembrolizumab monotherapy improved survival outcomes compared to the chemotherapy arm. So, in this exploratory analysis presented at ASCO24, Dr. Tom Powles and colleagues sought to assess the role of ctDNA as a potential biomarker between the pembrolizumab monotherapy arm and the chemotherapy arm. Tumor tissue mutations were evaluated using whole exome sequencing, and plasma ctDNA was assessed with the Guardant 360 assay. Changes in ctDNA from pre-treatment cycle 1 to on-treatment cycle 2, so 3 weeks post-baseline assessment, were quantified by the maximum variant allele frequency of tumor tissue-specific mutations.  Results showed that lower baseline ctDNA levels were associated with improved clinical outcomes of response in the pembrolizumab arm but not in the chemotherapy arm. This improvement in the pembrolizumab arm was also robust to adjustment for tumor mutational burden and PD-L1. Additionally, chemotherapy led to a ctDNA clearance rate of 41% compared to 11% in the pembrolizumab arm. Patients who had a large ctDNA reduction with pembrolizumab had significantly improved outcomes compared to those achieving a large reduction with chemotherapy with a hazard ratio of 0.25. However, this did not replicate in patients who did not achieve a large reduction, as these patients had similar outcomes across both arms. Let's switch gears to kidney cancer and start with Abstract 4508, reporting the final OS analysis from the JAVELIN Renal-101 trial. Neeraj, what would you like to tell us about this abstract? Dr. Neeraj Agarwal:  Well, as a quick reminder, the JAVELIN Renal-101 was a randomized phase 3 trial where patients with previously untreated advanced or metastatic clear cell renal cell carcinoma were randomized to receive either the combination of avelumab plus axitinib or sunitinib. In previous analyses, the combination of avelumab and axitinib significantly improved PFS compared to sunitinib and was subsequently approved by the FDA for the first-line treatment of patients with advanced RCC in 2019. This superiority in PFS was maintained across the different analyses; however, OS data remained immature. In the abstract presented at ASCO24 by Dr. Robert Motzer from Memorial Sloan Kettering Cancer Center and colleagues, the authors reported OS results at a median follow-up of around 73 months and a minimum of 68 months for all patients, which is the longest follow-up for any ICI-TKI combination in RCC. The final analysis in the overall population favored the combination of avelumab plus axitinib with a median OS of 44.8 months compared to 38.9 months with sunitinib, however, this did not reach statistical significance with a hazard ratio of 0.88. The PFS results and safety profile were consistent with previous analyses.  Dr. Rana McKay: Thank you, Neeraj, for such a nice overview of this abstract. These new data could make this regimen less optimal than other ICI-TKI combinations in the first-line mRCC setting.   Dr. Neeraj Agarwal: I concur, Rana. Moving on to perhaps one of the most exciting GU abstracts featured, Abstract 4506, titled “Circulating kidney injury molecule-1 biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection.” Rana, what are your thoughts on this abstract? Dr. Rana McKay: Well, first, I would like to take a step back and remind our audience that in the IMmotion010 trial, patients with resected intermediate to high-risk RCC with clear cell and/or sarcomatoid component were randomized in a 1:1 ratio to receive either atezolizumab or placebo. Investigator-assessed disease-free survival, which was the primary endpoint, favored the atezolizumab arm but did not reach statistical significance. In the abstract featured at ASCO24, Dr. Laurence Albiges and colleagues build on data previously reported in the ASSURE and CheckMate 914 trials and report provocative findings regarding a molecule known as kidney injury molecule 1 or KIM-1, which is a type 1 membrane glycoprotein that has been identified as a minimally invasive potential peripheral blood circulating biomarker. The KIM-1 level of 86 pg/ml was identified as the optimized threshold for defining post-nephrectomy KIM-1 high vs KIM-1 low subgroups in the IMmotion010 trial. KIM-1 levels were measured at baseline or pre-treatment, at cycle 4 day 1, and at disease recurrence or discontinuation without disease recurrence. Baseline characteristics were balanced between the KIM-1 high and KIM-1 low groups, except perhaps for a slightly higher pathological stage in the KIM-1 high subgroup.  I would like to highlight 3 key takeaways from this abstract. First, KIM-1 high level was associated with significantly worse DFS with a hazard ratio of 1.75. Second, patients in the KIM-1 high subgroup receiving atezolizumab had a 28% reduction in the risk of recurrence or death compared to those receiving placebo, while those in the KIM-1 low subgroup had comparable outcomes across both treatment arms. Third, patients in the KIM-1 high subgroup receiving atezolizumab were significantly less likely to experience an on-treatment increase in KIM-1 levels, which was associated with worse DFS in both high and low KIM-1 subgroups, regardless of treatment arm. Thus, these findings support the use of KIM-1 as both a predictive and prognostic biomarker in patients with RCC. Dr. Neeraj Agarwal: Yes, Rana, this is amazing data! I would like to add that these results warrant larger and, ideally, prospective studies to validate the utility of KIM-1 as a noninvasive biomarker for identifying minimal residual disease after nephrectomy and for predicting outcomes to immune checkpoint inhibitors. Dr. Rana McKay: Also, in the field of biomarkers, 2 abstracts interrogating different biomarkers in a different setting, so in patients with advanced or metastatic RCC were presented. Neeraj, could you tell us more about these abstracts? Dr. Neeraj Agarwal: Of course! I think you are referring to Abstracts 4504 and 4505. In abstract 4504, Dr. Toni Choueiri and colleagues sought to assess the clinical implications of different biomarkers in the CLEAR trial, which was a randomized phase 3 trial that led to the approval of the combination of pembrolizumab plus lenvatinib in the first-line mRCC setting. On the other hand, in abstract 4505, Dr. Brian Rini presented biomarker results in KEYNOTE-426, which was also a randomized phase 3 trial based on which the combination of pembrolizumab plus axitinib was approved in patients with mRCC. The authors in both trials sought to investigate the role of biomarkers in predicting treatment outcomes from 3 different angles. Starting with PD-L1 expression, the superiority of the combination arms over sunitinib was not impacted by PD-L1 status in both trials. Moving on to RCC driver gene mutations on whole exome sequencing, such as VHL, SETD2, PBRM1, and BAP1, ICI combination therapies improved outcomes regardless of mutation gene status, and this improvement was statistically significant with PBRM1 mutations in KEYNOTE-426 compared to wild-type PBRM1, but this did not replicate in the CLEAR trial. Finally, using transcriptomic signatures derived from RCC trials, especially the IMmotion 151 and JAVELIN Renal 101 trials, where 7 clusters or molecular subtypes were identified, the combination arms outperformed sunitinib in all clusters in both trials and the magnitude of this benefit differed across clusters.  Dr. Rana McKay: Thank you for this very interesting summary and comparison of the results of these 2 abstracts. These findings support the use of ICI-based combinations in all patients with mRCC as a first-line option. Although these abstracts could not identify specific biomarkers that could guide us clinicians in treatment selection, they provide very interesting biological insights on these molecular biomarkers that are, however, not yet clinically actionable. Dr. Neeraj Agarwal: Very interesting point, Rana. Moving on to prostate cancer, let's start with abstract LBA5000 titled, “Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).” Rana, what is your takeaway on this abstract? Dr. Rana McKay: As a reminder to our audience, the CHAARTED2 trial was a randomized open-label phase 2 study that compared the combination of cabazitaxel and abiraterone to abiraterone alone in patients with mCRPC previously treated with ADT plus docetaxel in the hormone-sensitive setting. The primary endpoint was progression-free survival. After a median follow-up of 47.3 months, Dr. Christos Kyriakopoulos and colleagues reported in LBA5000 that patients receiving the combination of cabazitaxel plus abiraterone had a 27% reduction in the risk of progression or death. However, there was no significant difference in overall survival between the two arms, with a median OS of 25 months in the cabazitaxel+abiraterone arm and 26.9 months in the abiraterone arm, although the study was underpowered for this endpoint. Regarding the toxicity profile, the combination of cabazitaxel and abiraterone was overall well tolerated with more cytopenias, as expected.  Dr. Neeraj Agarwal: Very nice summary of this abstract, Rana. I would like to add that the treatment landscape of patients with mHSPC has evolved since the design of the study and now includes combination therapies of ADT + ARPI with or without docetaxel, and ADT + docetaxel is no longer a standard of care, which limits the applicability of these results in clinical practice today.  Dr. Rana McKay: Excellent point, Neeraj. Let's discuss Abstract 5001, titled “CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer”. Dr. Neeraj Agarwal: Sure! In the abstract featured at ASCO24, Dr. Matthew Smith and colleagues report the primary results of the CYCLONE 2 trial, which was a randomized phase 2/3 study that investigated the combination of abemaciclib plus abiraterone versus abiraterone monotherapy in patients with mCRPC. Stratification factors included radiographic progression at study entry, presence of measurable disease, and prior docetaxel for mHSPC. Part 1 of the study established the recommended phase 2 dose of abemaciclib at 200 mg twice daily. In part 2, patients were randomized to placebo or abemaciclib, and an adaptive interim analysis using prespecified criteria was performed and recommended the expansion of the study to part 3. The primary endpoint was investigator-assessed radiographic progression-free survival by RECIST 1.1 and PCWG3 criteria in the intention-to-treat population. At the time of the primary analysis, adding abemaciclib to abiraterone did not improve rPFS, with a hazard ratio of 0.83. The median rPFS was 22 months for the combination arm and 20.3 months for the abiraterone arm. The combination was well tolerated, and the safety profile was consistent with the known adverse events. Dr. Rana McKay: So, the addition of abemaciclib to abiraterone did not improve outcomes in patients with mCRPC. These findings suggest that no further investigation is warranted for abemaciclib or CDK4/6 inhibitors in biomarker-unselected patients with prostate cancer.  Dr. Neeraj Agarwal: Rana, what's your take-home message on Abstract 5006, titled “Health-related quality of life results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer”? Dr. Rana McKay: So, as a reminder to our audience, the PRESTO trial was a randomized phase 3 study that assessed the effects of intensified androgen receptor blockade in patients with biochemically recurrent prostate cancer following local therapies. Patients with a PSA doubling time of less than 9 months and no evidence of metastatic disease were randomized to receive either 52 weeks of ADT alone, ADT plus apalutamide, or ADT plus apalutamide plus abiraterone. In their paper published earlier this year in the Journal of Clinical Oncology, the authors showed that patients receiving ADT plus apalutamide with or without abiraterone had significantly longer PSA-progression-free survival than those receiving ADT alone. In the oral presentation featured at ASCO24, Dr. Ronald Chen and colleagues report health-related quality of life outcomes that were assessed using various questionnaires or scales at baseline, at cycle 7, which is around 6 months on treatment, and at the end of treatment. Results showed that this intensified approach with apalutamide did not significantly increase severe adverse events, did not lengthen the time to testosterone recovery, and did not meaningfully increase common treatment-related symptoms such as hormonal symptoms, sexual dysfunction, hot flash interference, and fatigue. Importantly, additional intensification with abiraterone did not further improve PSA-PFS but did increase the rate of serious adverse events, lengthened the time to testosterone recovery, and increased hot flash interference.  Dr. Neeraj Agarwal: So, in conclusion, the PRESTO trial supports using intensified androgen blockade with apalutamide to improve PSA-PFS in patients with high-risk biochemically recurrent prostate cancer without compromising health-related quality of life. However, adding abiraterone did not offer additional benefits and increased side effects.  Dr. Rana McKay: Let's move on to LBA5002 titled, “A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.” Would you like to share your insights on this abstract with our listeners? Dr. Neeraj Agarwal: Absolutely. MAST was a randomized, double-blinded, placebo-controlled trial that investigated the impact of metformin on the progression of low-risk localized prostate cancer in patients choosing to undergo active surveillance. Eligible patients had biopsy-proven, low-risk, localized prostate cancer diagnosed within the past 6 months, characterized by a Gleason score of less than 6 observed in less than one-third of the total cores, less than 50% positivity in any one core, a PSA level of less than 10 ng/ml, and a clinical-stage between T1c and T2a. Patients were randomized in a 1:1 ratio to receive either metformin 850 mg twice daily or placebo for three years. All patients underwent repeat prostate biopsy at 18 and 36 months. The primary endpoint was time to progression, defined as the earliest occurrence of primary prostate cancer therapy, such as prostatectomy, radiation, hormonal therapy, or pathological progression on subsequent biopsies, which was defined as more than 1/3 of total cores involved, at least 50% of any one core involved, or Gleason pattern 4 or higher. The study included 407 patients, with 204 receiving metformin and 203 receiving a placebo. Results presented by Dr. Anthony Joshua showed no statistically significant difference in progression-free survival, including therapeutic and pathologic progression, with an unadjusted hazard ratio of 1.08.  Interestingly, there was a signal that patients with a BMI more than 30 had a detriment to taking metformin with a higher risk of progression compared to those receiving placebo with an unadjusted HR of 2.39 and a p-value of 0.01. Dr. Rana McKay: I would like to add that this study showed that metformin use does not prevent the progression of low-risk localized prostate cancer on active surveillance and could represent a potential detriment for patients with high BMI at study entry. Dr. Neeraj Agarwal: Yes, Rana, I concur. Any final remarks before we conclude today's podcast? Dr. Rana McKay:  Thank you, Neeraj; it's been wonderful being here with you today and you having me on the podcast to highlight these important advances and the amazing work that many investigators are conducting and the patients who were involved in the context of these trials. It's really excellent to see these updated results.   Dr. Neeraj Agarwal: Before we wrap up this podcast, I would like to say that we have reviewed a selection of abstracts addressing prostate, bladder, and kidney cancer, which are significantly impacting our medical practices now and in the near future. Rana, thank you for sharing your insights today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion. Many thanks. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Find out more about today's speakers:    Dr. Neeraj Agarwal   @neerajaiims   Dr. Rana McKay  @DrRanaMcKay     Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn         Disclosures:        Dr. Neeraj Agarwal:         Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences     Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas      Dr. Rana McKay:   Consulting or Advisory Role: Janssen, Novartis, Tempus, Exelxis, Pfizer, Bristol-Myers Squibb, Astellas Medivation, Dendreon, Bayer, Sanofi, Merck, Vividion, Calithera, AstraZeneca, Myovant, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Pfizer, Bayer, Tempus

The Fierce Female Network
Fake Ozempic Is Circulating, Doctors, Demons & Medicine

The Fierce Female Network

Play Episode Listen Later Jun 21, 2024 24:00


(Bloomberg) -- The World Health Organization warned that fake batches of Novo Nordisk A/S's hit diabetes drug Ozempic have been circulating amid soaring demand for the medicine, which some patients use to lose weight.  Three falsified batches were identified in Brazil and the UK in October of last year and in the US in December, the WHO said on Thursday. Though the global public health body has been monitoring growing numbers of reports of fake semaglutide, as Ozempic is known generically, since 2022, this is the first time it has issued an official warning notice.

Weightlifting Talk
Circulating gym / SOLO / June 17th 2024

Weightlifting Talk

Play Episode Listen Later Jun 17, 2024 36:33


Weightlifting Talk

SLEEP
Meditation (3 Hours): Body Relaxing Affirmations for Sleep

SLEEP

Play Episode Listen Later Jun 11, 2024 181:30


Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

Behind The Knife: The Surgery Podcast
Journal Review in Hepatobiliary Surgery: ctDNA & Colorectal Liver Metastasis

Behind The Knife: The Surgery Podcast

Play Episode Listen Later May 2, 2024 34:33


Circulating tumor DNA, more commonly referred to as ctDNA, has emerged as an attractive and potentially highly sensitive biomarker for patients with colorectal cancer. But what exactly is ctDNA, does it have any prognostic value for patients with colorectal liver metastasis, and how can it be incorporated into the management of said patients? In this episode from the HPB team at Behind the Knife, listen in on the discussion about ctDNA and its role in the perioperative management of colorectal liver metastasis.   Hosts Anish J. Jain MD (@anishjayjain) is a T32 Research Fellow at the University of Texas MD Anderson Cancer Center within the Department of Surgical Oncology. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology. He is also the associate program director of the HPB fellowship at the University of Texas MD Anderson Cancer Center.  Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center Learning Objectives: -Develop an understanding of what circulating tumor DNA (ctDNA) is.  -Develop an understanding of what makes ctDNA unique from other “tumor markers” like CEA. -Develop an understanding of the prognostic value of ctDNA for colorectal liver metastasis (CRLM).  -Develop an understanding of the current role of ctDNA in the perioperative treatment of patients with CRLM. -Develop an understanding of how ctDNA can be incorporated into future treatment algorithms for patients undergoing hepatic resection for CRLM. Papers Referenced (in the order they were mentioned in the episode): 1)    Newhook TE, Overman MJ, Chun YS, et al. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2023;277(5):813-820. https://pubmed.ncbi.nlm.nih.gov/35797554/ 2)    Nishioka Y, Chun YS, Overman MJ, et al. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2022;234(4):474-483. https://pubmed.ncbi.nlm.nih.gov/35290266/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Sleep Meditation for Women 3 HOURS
Meditation: Body Relaxing Affirmations for Sleep

Sleep Meditation for Women 3 HOURS

Play Episode Listen Later May 1, 2024 181:30


Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

Curiosity Daily
Stress & Immunity, Crop Resilience, Psychedelic Scale

Curiosity Daily

Play Episode Listen Later Mar 20, 2024 13:17


Today, you'll learn about the surprising effect our immune system has on our emotional health, a new discovery about the biological clock of plants, and how researchers are rediscovering the science of psychedelics. Stress & Immunity “Mount Sinai Study Shows That Circulating Immune Cells Drawn to the Brain During Stress Can Control Emotional Behaviors.” Mt. Sinai. 2024. “Major Depressive Disorder.” by Navneet Bains & Sara Abdijadid. 2023. “Circulating myeloid-derived MMP8 in stress susceptibility and depression.” by Flurin Cathomas, et al. 2024. Crop Resilience “USC researchers uncover biological circuit that protects plants from extreme conditions.” EurekAlert! 2024. “Climate Change Impacts on Agriculture and Food Supply.” EPA. 2023. “The interplay between the circadian clock and abiotic stress responses mediated by ABF3 and CCA1/LHY.” by Tong Liang, et al. 2024. Psychedelic Scale “An intriguing psychedelic assessment is back from the dead, thanks to Swiss scientists.” by Eric W. Dolan. 2024. “The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.” by Tomas Frymann, et al. 2022. “The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.” by Kurt Stocker, et al. 2023. Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

Tha Boxing Voice
☎️Edgar Berlanga Vs. Daniel Jacobs

Tha Boxing Voice

Play Episode Listen Later Mar 12, 2024 120:18


#edgarberlanga #danieljacobs #canelo ️️️☎️Edgar Berlanga Vs. Daniel Jacobs